Evidence map›Paper›PMID 35628616›Full record

ArticleInternational journal of molecular sciences2022

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized

Fukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, Takashi Masuko, Yuichi Endo, Chika Igarashi, Tomoko Tachibana, Mitsuhiro Shinada, Ming-Rong Zhang, Gene Kurosawa and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Fukiko HiharaDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroki MatsumotoDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Mitsuyoshi YoshimotoDivision of Functional Imaging, National Cancer Center Hospital East, Chiba 277-8577, Japan.
Takashi MasukoSchool of Pharmacy, Kindai University, Osaka 577-8502, Japan.ORCID 0000-0002-2410-2007
Yuichi EndoSchool of Pharmacy, Kindai University, Osaka 577-8502, Japan.
Chika IgarashiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Tomoko TachibanaDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Mitsuhiro ShinadaDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.ORCID 0000-0003-4244-8914
Ming-Rong ZhangDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Gene KurosawaInternational Center for Cell and Gene Therapy, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0001-9477-7467
Aya SugyoDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.ORCID 0000-0003-2726-288X
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroaki KuriharaDepartment of Diagnostic Radiology, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.ORCID 0000-0003-4480-0029
Yukie YoshiiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
National Institutes for Quantum Science and Technology · JPKanagawa Prefectural Hospital Organization · JPKindai University · JPFujita Health University · JPNational Cancer Center Hospital East · JPToho University · JP

Funding

Japan Agency for Medical Research and Development JP17cm0106225h0002Japan Agency for Medical Research and Development JP20cm0106479h001MEXT/JSPS KAKENHI 18H05463
6 · The paper itself

Abstract

Peritoneal dissemination of pancreatic cancer has a poor prognosis. We have reported that intraperitoneal radioimmunotherapy using a

Indexed as

Pancreatic NeoplasmsRadioimmunotherapyAnimalsCell Line, TumorDisease Models, AnimalFeasibility StudiesHumansMice64Cu-intraperitoneal radioimmunotherapyin vitro tumor cell-binding assaypancreatic cancerperitoneal dissemination

Identifiers

PMID35628616
PMCPMC9146758
OpenAlexW4281251190

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.